---
title: "FLGT: Revenue rose 4% year-over-year, but guidance was lowered due to billing transition impacts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294421625.md"
description: "Q2 2026 revenue grew 4% year-over-year to $85.4 million, driven by acquisitions and innovation in AI and pathology, but margins and guidance were impacted by billing system transition and lower collection rates. Full-year revenue guidance was revised down to $330–$340 million.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T21:56:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294421625.md)
  - [en](https://longbridge.com/en/news/294421625.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294421625.md)
generator: "portal-rs"
---

# FLGT: Revenue rose 4% year-over-year, but guidance was lowered due to billing transition impacts

Q2 2026 revenue grew 4% year-over-year to $85.4 million, driven by acquisitions and innovation in AI and pathology, but margins and guidance were impacted by billing system transition and lower collection rates. Full-year revenue guidance was revised down to $330–$340 million.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [FLGT.US](https://longbridge.com/en/quote/FLGT.US.md)

## Related News & Research

- [Fulgent Genetics Q2 revenue rises 20% sequentially, sees billing system transition delay](https://longbridge.com/en/news/294410077.md)
- [MaxLinear (MXL) Draws Fresh Attention, Does It Look Fully Valued?](https://longbridge.com/en/news/300242448.md)
- [China’s consumer stocks face lost decade](https://longbridge.com/en/news/300225845.md)
- [ACET: Prula-cel showed high remission rates and favorable safety in SLE, supporting pivotal trial plans](https://longbridge.com/en/news/300296638.md)
- [GRAPHIC-Take Five: It's Q4 already?](https://longbridge.com/en/news/300262226.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**